Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Finished Goods (2016 - 2018)

Historic Finished Goods for Vanda Pharmaceuticals (VNDA) over the last 5 years, with Q1 2018 value amounting to $1.0 million.

  • Vanda Pharmaceuticals' Finished Goods rose 3198.43% to $1.0 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.0 million, marking a year-over-year increase of 3198.43%. This contributed to the annual value of $760000.0 for FY2017, which is 26.25% down from last year.
  • According to the latest figures from Q1 2018, Vanda Pharmaceuticals' Finished Goods is $1.0 million, which was up 3198.43% from $760000.0 recorded in Q4 2017.
  • Vanda Pharmaceuticals' 5-year Finished Goods high stood at $3.4 million for Q4 2014, and its period low was $611000.0 during Q2 2017.
  • Over the past 5 years, Vanda Pharmaceuticals' median Finished Goods value was $941000.0 (recorded in 2014), while the average stood at $1.5 million.
  • Within the past 5 years, the most significant YoY rise in Vanda Pharmaceuticals' Finished Goods was 18119.02% (2015), while the steepest drop was 6187.39% (2015).
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Finished Goods stood at $3.4 million in 2014, then tumbled by 61.87% to $1.3 million in 2015, then tumbled by 41.11% to $762000.0 in 2016, then decreased by 0.26% to $760000.0 in 2017, then surged by 33.03% to $1.0 million in 2018.
  • Its Finished Goods stands at $1.0 million for Q1 2018, versus $760000.0 for Q4 2017 and $858000.0 for Q3 2017.